Search PubMed⌕ Search

Biomedical subjects

L Schertel

Publications and source records attributed to L Schertel.

At least 19 recordsLinked to original sources
PubMed1986

[Results of percutaneous radiotherapy of mostly advanced cancers of the tongue].

A retrospective study compiles the therapy results of 164 evaluable patients with lingual tumors who had been irradiated primarily or as part of a combined surgical-radio-oncologic treatment scheme at the Radiologic Hospital of the University of Münster. The five-year survival rate of all patients in all stages is 22%, and there were no statistically significant differences in the prognosis of carcinomas of the body of the tongue (22%) and carcinomas of the base of the tongue (25%). Our own experiences as well as the communications in literature show that the dose necessary, depending on the stage, is 55 to 60 Gy for small tumors (stages I and II), given within six weeks into the region of the primary tumor. In case of extended tumors (stages III and IV), 60 to 70 Gy have to be administered in seven to eight weeks. The split-course irradiation applied in our own cases produced a small rate of side effects without any demonstrable bad influence on the prognosis. For the irradiation of regional lymph nodes which has to be performed after neck dissection, too, 45 to 50 Gy should be given within four to five weeks. This dose should be increased by about 10 to 15 Gy in case of manifestations in extended regions. The excellent efficiency of intraoral electron irradiation is pointed out.

Adult↗
PubMed1986

[Radiotherapy results in advanced hypopharyngeal tumors].

A retrospective study was made on 57 cases with mostly advanced hypopharyngeal tumors. The patients were irradiated between 1960 and the end of 1983 at the Radiologic Hospital of the University of Münster. 39 patients were submitted for radiotherapy as primary treatment, nine patients were irradiated postoperatively, and nine further patients received adjuvant cytostatic chemotherapy. The overall five-year survival rate was 16%. 19% out of all patients developed recurrences within one year following the treatment.

Adult↗
PubMed1986

[Radiotherapy of penis and urethral cancers].

A stage dependent combined procedure of surgery and radiotherapy should be performed in penile carcinoma. Including all stages a local tumor control rate of 85% can be achieved if a radiation dosage of at least 55-60 Gy is applied. Surgery of recurrences is not impaired after radiotherapy. Prophylactic irradiation of regional lymph nodes should be performed in all tumors with more than T2 extension and in tumors located at the base of the Penis. Carcinoma of the urethra in general should be treated primarily by surgery, but in advanced tumors and in old patients a combined procedure of surgery and irradiation can be recommended. Prophylactic irradiation of the regional lymph nodes should be performed in tumors located in the proximal part of the urethra. In certain cases of infiltration of the bladder iliac lymph nodes should be irradiated as well. The results of 63 patients with penile carcinoma and 13 cases of carcinoma of the urethra are reported.

Brachytherapy↗
PubMed1985

[Treatment results of advanced tonsillar tumors].

The authors present 99 patients irradiated for a tonsillar carcinoma. 41 patients were primarily irradiated and 52 patients postoperatively. Radiotherapy was combined with cytostatic chemotherapy in six cases. Most of the cases treated were advanced tumors: 76 patients with T3/T4 tumors. 52% out of the 23 patients with T1/T2 tumors survived five years and 45% ten years; only 26% of the patients with T3 tumors and 15% of those with T4 tumors survived five years. The prognosis was significantly influenced by the lymph node state: whereas 75% of the patients with N0 tumors survived five years, this rate is reduced to 21% in case of lymph node state N3. 22 out of the 34 recurrences were situated in the tumor region, 12 in lymph nodes. 94% of recurrences became evident during the first two years after the end of treatment.

Antineoplastic Agents↗